NCT06494943View on ClinicalTrials.gov

Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

June 26, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Head and Neck CancerHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

Sintilimab

PD-1 inhibitor

DRUG

IBI110

LAG-3 inhibitor

DRUG

Paclitaxel

Chemotherapy

DRUG

Cis Platinum

Chemotherapy

PROCEDURE

Surgery

Definitive surgery

RADIATION

Adjuvant radiation

Adjuvant radiotherapy or chemoradiotherapy based on post-operative pathologic findings.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER